Morgan Stanley Cellectis S.A. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Cellectis S.A. stock. As of the latest transaction made, Morgan Stanley holds 84,145 shares of CLLS stock, worth $171,655. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,145

Previous 76,225 10.39%

Holding current value

$171,655

Previous $234,000 5.13%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.41 - $3.09 $19,087 - $24,472	7,920 Added 10.39%	84,145 $222,000
Q4 2023 Feb 13, 2024	BUY	$0.97 - $3.55 $8,374 - $30,647	8,633 Added 12.77%	76,225 $234,000
Q3 2023 Nov 15, 2023	SELL	$1.58 - $2.86 $15,104 - $27,341	-9,560 Reduced 12.39%	67,592 $106,000
Q2 2023 Aug 14, 2023	SELL	$1.72 - $2.12 $946 - $1,166	-550 Reduced 0.71%	77,152 $151,000
Q1 2023 May 15, 2023	BUY	$1.83 - $3.84 $6,516 - $13,674	3,561 Added 4.8%	77,702 $149,000

Q4 2022 Feb 14, 2023	SELL	$1.85 - $2.53 $3,352 - $4,584	-1,812 Reduced 2.39%	74,141 $155,000
Q3 2022 Nov 14, 2022	SELL	$2.42 - $4.08 $58,075 - $97,911	-23,998 Reduced 24.01%	75,953 $174,000
Q2 2022 Oct 27, 2022	BUY	$2.39 - $4.93 $41,922 - $86,477	17,541 Added 21.29%	99,951 $283,000
Q2 2022 Aug 15, 2022	BUY	$2.39 - $4.93 $41,922 - $86,477	17,541 Added 21.29%	99,951 $283,000
Q1 2022 Oct 27, 2022	SELL	$3.45 - $8.77 $60,516 - $153,834	-17,541 Reduced 17.55%	82,410 $374,000
Q1 2022 May 13, 2022	SELL	$3.45 - $8.77 $129,571 - $329,374	-37,557 Reduced 31.31%	82,410 $374,000
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $67,163 - $107,663	-8,385 Reduced 6.53%	119,967 $974,000
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $1.53 Million - $2.07 Million	128,352 New	128,352 $1.62 Million

Others Institutions Holding CLLS

# of Institutions

Shares Held

9.83M

Call Options Held

Put Options Held

30.9K

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $92.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account